COPD - what has changed in GOLD 2023 and is relevant for clinical practice?

被引：0

作者：

Klemmer, Andreas ^{[1
]}

Alter, Peter ^{[1
]}

Vogelmeier, Claus F. ^{[1
,2
]}

机构：

[1] Deutsch Zentrum Lungenforsch, Klin Innere Med Schwerpunkt Pneumol Intens & Schla, UKGM, Marburg, Germany

[2] Baldingerstr, D-35043 Marburg, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2023年 / 148卷 / 12期

关键词：

COPD; diagnostics; therapy; guideline; OBSTRUCTIVE PULMONARY-DISEASE; DIAGNOSIS;

D O I：

10.1055/a-1997-1375

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The annual report of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) is one of the most relevant documents covering prevention, diagnosis and treatment of chronic obstructive pulmonary disease (COPD). The 2023 edition contains a number of changes with impact on clinical practice. For assessment and categorization, a new patient group termed E based on individual exacerbation history has been introduced. The basis of pharmacological management for most patients is the use of combinations containing a long acting beta 2-agonist (LABA) and a long-acting anticholinergic (LAMA). Combinations of LABA and inhaled corticosteroids (ICS) are no longer recommended. When there is an indication for ICS therapy, a combination of LABA, LAMA and ICS should be used. For these triple combinations, a significant reduction of mortality could be demonstrated in selected patient populations. GOLD proposes a new definition and assessment of COPD exacerbations focussing on objectively assessible parameters and relevant differential diagnoses.

引用

页码：780 / 787

页数：8

共 25 条

[21] Guideline for the Diagnosis and Treatment of COPD Patients Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology [J].

Vogelmeier, C. ;

Buhl, R. ;

Burghuber, O. ;

Criee, C. -P. ;

Ewig, S. ;

Godnic-Cvar, J. ;

Hartl, S. ;

Herth, F. ;

Kardos, P. ;

Kenn, K. ;

Nowak, D. ;

Rabe, K. F. ;

Studnicka, M. ;

Watz, H. ;

Welte, T. ;

Windisch, W. ;

Worth, H. .

PNEUMOLOGIE, 2018, 72 (04) :253-308

[22]

Vogelmeier C., 2017, BRN REV, V3, P151

[23] Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease [J].

Wedzicha, Jadwiga A. ;

Brill, Simon E. ;

Allinson, James P. ;

Donaldson, Gavin C. .

BMC MEDICINE, 2013, 11

[24] Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial [J].

Wells, J. Michael ;

Criner, Gerard J. ;

Halpin, David M. G. ;

Han, MeiLan K. ;

Jain, Renu ;

Lange, Peter ;

Lipson, David A. ;

Martinez, Fernando J. ;

Midwinter, Dawn ;

Singh, Dave ;

Wise, Robert A. .

CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2023, 10 (01) :33-45

[25] In 'real world' patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations [J].

Worth, Heinrich ;

Buhl, Roland ;

Criee, Carl-Peter ;

Kardos, Peter ;

Gueckel, Eva ;

Vogelmeier, Claus F. .

RESPIRATORY RESEARCH, 2023, 24 (01)

← 1 2 3 →